MLV & Co. Upgrades Cytokinetics (CYTK) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.33 -0.84%
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
MLV & Co. upgraded Cytokinetics (NASDAQ: CYTK) from Hold to Buy with a price target of $9.00.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $3.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Texas Instruments (TXN) to Buy
- CBRE Equity Research Upgrades MGM Resorts (MGM) to Buy
- BNP Paribas Exane Upgrades Tesla (TSLA) to Neutral
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
